Anticonvulsants and anxiolytics: Barbiturates

30,733views

Anticonvulsants and anxiolytics: Barbiturates

Watch later

Watch later

Nernst equation
Cytoskeleton and intracellular motility
Cell signaling pathways
Resting membrane potential
Gene regulation
Epigenetics
Nuclear structure
DNA structure
Transcription of DNA
Amino acids and protein folding
Necrosis and apoptosis
Endometrial hyperplasia and cancer: Clinical
Lung cancer and mesothelioma: Pathology review
Metaplasia and dysplasia
Oral cancer
Testicular cancer
Lung cancer
Asthma
Atrial septal defect
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Acute respiratory distress syndrome
Angina pectoris
Aortic valve disease
Bronchiectasis
Chronic bronchitis
Chronic venous insufficiency
Coarctation of the aorta
Deep vein thrombosis
Emphysema
Endocarditis
Gas exchange in the lungs, blood and tissues
Heart failure
Mitral valve disease
Cor pulmonale
Heart failure: Pathology review
Myocarditis
Diabetes mellitus: Pathology review
Adrenocorticotropic hormone
Chlamydia trachomatis
Cortisol
Abnormal uterine bleeding: Clinical
Cushing syndrome
Endometriosis
Glucagon
Glucocorticoids
Herpes simplex virus
HIV (AIDS)
Hypothyroidism: Pathology review
Hypothyroidism
Insulin
Neisseria gonorrhoeae
Pelvic inflammatory disease
Polycystic ovary syndrome
Benign prostatic hyperplasia
Thyroid hormones
Testosterone
Syndrome of inappropriate antidiuretic hormone secretion (SIADH)
Primary adrenal insufficiency
Hyperthyroidism: Pathology review
Chronic leukemia
Anemia of chronic disease
Hemophilia
Heparin-induced thrombocytopenia
Hypocalcemia
Hypermagnesemia
Hypokalemia
Hypomagnesemia
Inflammation
Innate immune system
Complement system
Iron deficiency anemia
Leukemias: Pathology review
Platelet disorders: Pathology review
Sickle cell disease (NORD)
Type IV hypersensitivity
Vaccinations
Acute pyelonephritis
Celiac disease
Cirrhosis
Congenital disorders: Clinical
Appendicitis
Autoimmune hepatitis
Bowel obstruction
Chronic cholecystitis
Chronic pyelonephritis
Crohn disease
Gastroesophageal reflux disease (GERD)
Nephrotic syndromes: Pathology review
Irritable bowel syndrome
Lower urinary tract infection
Biliary colic
Peptic ulcer
Renal failure: Pathology review
Urinary tract infections: Pathology review
Viral hepatitis
Pancreatitis: Pathology review
Alcohol-associated liver disease
Ulcerative colitis
Medullary cystic kidney disease
Small bowel ischemia and infarction
Chronic kidney disease
Acute cholecystitis
Skin cancer
Autosomal trisomies: Pathology review
Selective permeability of the cell membrane
Free radicals and cellular injury
Pericarditis and pericardial effusion
Peripheral artery disease
Cauda equina syndrome
Cranial nerves
Dementia: Pathology review
Arteriovenous malformation
Bipolar and related disorders
Seizures and epilepsy
Generalized anxiety disorder
Headaches: Pathology review
Huntington disease
Ischemic stroke
Major depressive disorder
Meningitis
Migraine
Multiple sclerosis
Myasthenia gravis
Panic disorder
Parkinson disease
Alzheimer disease
Approach to abnormal uterine bleeding in reproductive-aged patients: Clinical sciences
Coagulation disorders: Pathology review
Factor V Leiden
Hodgkin lymphoma
Disseminated intravascular coagulation
Non-Hodgkin lymphoma
Introduction to the immune system
Acute pancreatitis
Approach to congenital heart diseases (acyanotic): Clinical sciences
Acne vulgaris
Atopic dermatitis
Back pain: Pathology review
Bone disorders: Pathology review
Burns
Osteoarthritis
Osteoporosis
Paget disease of bone
Psoriasis
Rheumatoid arthritis
Varicella zoster virus
Introduction to pharmacology
Drug administration and dosing regimens
Enzyme function
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacokinetics: Drug absorption and distribution
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Desensitization and tolerance
Pharmacodynamics: Agonist, partial agonist and antagonist
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid use disorder
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid antagonists
Anticoagulants: Direct factor inhibitors
Anticoagulants: Heparin
Anticoagulants: Warfarin
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Role of Vitamin K in coagulation
Loop diuretics
Miscellaneous lipid-lowering medications
Potassium sparing diuretics
Adrenergic antagonists: Alpha blockers
Calcium channel blockers
Adrenergic antagonists: Beta blockers
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Class I antiarrhythmics: Sodium channel blockers
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
Positive inotropic medications
Anti-mite and louse medications
Antimalarials
Hepatitis medications
Anthelmintic medications
Integrase and entry inhibitors
Antimetabolites: Sulfonamides and trimethoprim
Azoles
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Echinocandins
Herpesvirus medications
Mechanisms of antibiotic resistance
Miscellaneous cell wall synthesis inhibitors
Miscellaneous protein synthesis inhibitors
Neuraminidase inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Protein synthesis inhibitors: Aminoglycosides
Protein synthesis inhibitors: Tetracyclines
Antihistamines for allergies
Miscellaneous antifungal medications
Antituberculosis medications
Androgens and antiandrogens
Aromatase inhibitors
Estrogens and antiestrogens
PDE5 inhibitors
Progestins and antiprogestins
Uterine stimulants and relaxants
Acid reducing medications
Antidiarrheals
Laxatives and cathartics
Non-corticosteroid immunosuppressants and immunotherapies
Hyperthyroidism medications
Hypoglycemics: Insulin secretagogues
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Mineralocorticoids and mineralocorticoid antagonists
Sympatholytics: Alpha-2 agonists
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Atypical antipsychotics
Atypical antidepressants
Typical antipsychotics
Lithium
Monoamine oxidase inhibitors
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Anti-parkinson medications
Tricyclic antidepressants
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Muscarinic antagonists
Migraine medications
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Antigout medications
Folate (Vitamin B9) deficiency
Vitamin D
Fat-soluble vitamin deficiency and toxicity: Pathology review
Approach to viral exanthems (pediatrics): Clinical sciences
Mumps virus
Measles virus
Rubella virus
Bordetella pertussis (Whooping cough)
Poliovirus

Transcript

Watch video only

Barbiturates are a class of medications that are used as anticonvulsants to manage seizure disorders; to induce anesthesia in surgical procedures; as anxiolytics to relieve anxiety; and to manage insomnia. Barbiturates enhance the effect of gamma-aminobutyric acid, or GABA, which is the major inhibitory neurotransmitter in the brain, by binding to its receptor.

It’s pretty well-established that your brain’s really important. It controls your feelings, your movements, your sleep, your memory… It controls everything, whether you’re aware of it or not. The cells that make up our brain are called neurons. Neurons communicate with each other through neurotransmitters. When one neuron is stimulated, it’ll release excitatory neurotransmitters like glutamate, which bind to receptors on the next neuron. This causes the next neuron to depolarize and release its own excitatory neurotransmitters, propagating the signal throughout the brain.

Now, we also have inhibitory neurons that will shut down this chain of events. These neurons release the main inhibitory neurotransmitter in the nervous system, gamma-aminobutyric acid, or GABA, which binds to GABA receptors on other neurons. These receptors are large multi-unit complexes that form ligand-gated ion channels, which open up to let Cl- ions into the cell. The influx of negatively charged ions causes hyperpolarization, where the cell’s membrane potential becomes more negative, which means it’s much more difficult for it to depolarize and fire off an action potential, and that means it’s less responsive to stimuli.

Now, there are cases where neurons in the brain start sending out more excitatory signals than normal. This can occur due to either too much excitation by the excitatory neurotransmitters, or too little inhibition by the inhibitory neurotransmitters like GABA. Excessive excitatory signals can cause psychiatric disorders like anxiety, and neurological disorders like seizures and epilepsy.

Okay, so one way we can decrease the excitatory signals is by enhancing the effect of inhibitory neurons through medication like barbiturates. Common medications in this class include amobarbital, butabarbital, methohexital, PENTobarbital, PHENobarbital, and primidone, which is a prodrug of PHENobarbital. Another medication from this group is thiopental, but it’s not available in the U.S. and Canada anymore. These medications target the GABAA receptors but they bind at a different site than GABA or benzodiazepines. At lower doses, barbiturates enhance the effect of GABA by increasing the duration of Cl- channels opening, thereby increasing the influx of Cl- ions. As a result, high intracellular concentrations of Cl- ions cause membrane hyperpolarization, which means it’s much more difficult for the neuron to depolarize and fire off an action potential. This differentiates them from benzodiazepines which also work by binding to GABAA receptors, but in contrast to barbiturates, they work by increasing the frequency of Cl- channels opening. So remember, barbiDurates increase duration! At higher doses, these medications can mimic GABA effect by triggering the opening of these channels even without GABA. In addition, barbiturates block excitatory glutamate receptors called AMPA receptors and decrease neuronal excitability; but they also inhibit voltage-gated calcium channels and decrease the release of glutamate.

Now, let’s draw a chart of the dose-dependent effects of barbiturates. On the left side of the chart, let’s place central nervous effects; and on the bottom let’s place dose. Low doses of barbiturates cause sedation, disinhibition, and anxiolysis; but as the dose increases, barbiturates cause hypnosis, anesthesia, medullary depression, and eventually coma

Now at a higher dose, barbiturates also inhibit the electron transport chain, which is a process that occurs within the inner mitochondrial membrane and results in the synthesis of adenosine triphosphate, or ATP. ATP is the main form of energy that keeps all of our body cells going. So when the electron transport chain gets interrupted, the ATP synthesis doesn’t happen and that can eventually lead to the death of the cell. Barbiturates also induce a class of enzymes called cytochrome P450. These enzymes are involved in the metabolism of various medications like benzodiazepines, phenytoin, quinidine, warfarin, and others. Increased cytochrome P450 activity can cause these medications to break down more rapidly, so larger doses may be needed to achieve a therapeutic effect.  

Alright, now barbiturates are indicated when the neurons get “super excited” and we want to calm them down, like during an epileptic seizure where clusters of neurons in the brain become temporarily impaired and start firing off a ton of excitatory signals. Moreover, PHENobarbital is the first-line treatment for neonatal convulsions. Also, this feature makes them useful for treating acute anxiety states like a panic attack. In addition, barbiturates can be used for preoperative sedation and to induce anesthesia; but they can also be given as a hypnotic to induce sleep since we basically want to depress the function of the person’s nervous system. Finally, in life-threatening conditions, such as increased intracranial pressure, these medications can be used to decrease cerebral blood flow and induce coma, which is also known as the barbiturate-induced coma.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Does bright light have an anxiolytic effect? - an open trial" BMC Psychiatry (2007)
  5. "The use of phenobarbital and other anti-seizure drugs in newborns" Seminars in Fetal and Neonatal Medicine (2017)
  6. "Pediatric Epilepsy" Demos Medical Pub (2001)
  7. "Comparison of the effectiveness of phenobarbital, mephobarbital, primidone, diphenylhydantoin, ethotoin, metharbital, and methylphenylethylhydantoin in motor seizures" Clinical Pharmacology & Therapeutics (1962)